AstraZeneca Ends AZD9412 IFN-β Asthma Trial For Redesign, Relaunch
Executive Summary
AstraZeneca is stopping a Phase IIa trial assessing in-licensed AZD9412's effect on asthma patients because fewer of them than expected had their condition worsen, making it difficult for the respiratory specialist to gauge the drug's efficiency. AstraZeneca will now re-design the endpoints and resume the study in 2017.
You may also be interested in...
Synairgen Stock Soars 420% On Promise Of Inhaled COVID-19 Drug
Preliminary results show that hospitalized coronavirus patients who received Synairgen's inhaled interferon beta product had a 79% lower risk of developing severe disease compared with placebo.
Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market
AstraZeneca hopes its investigative biologic benralizumab has strongly differentiated itself from rival therapies Nucala and Cinqair with the detailed publication of Phase III data showing it significantly cut exacerbations and improved lung function and symptoms in patients with severe eosinophilic asthma, as well as offering a favorable dosing schedule.
Synairgen, Pharmaxis Pair Up On LOXL2 Lung Disease Therapy
UK biotechnology company Synairgen plc is teaming up with Australian pharmaceutical company Pharmaxis Ltd to develop a new drug for idiopathic pulmonary fibrosis (IPF) which it hopes to pair up with a big pharma on later down the line.